Investigating viral glycosylation pathways for drug and vaccine development by Brun, J

An update on SARS-CoV-2 clinical trial results—what we can learn for the next pandemic by Arman, BY, Brun, J, Hill, ML, Zitzmann, N, von Delft, A

Antiviral effects of deoxynojirimycin (DNJ)-based iminosugars in dengue virus-infected primary dendritic cells by Perera, N, Brun, J, Alonzi, DS, Tyrrell, BE, Miller, JL, Zitzmann, N

Lipid composition but not curvature is the determinant factor for the low molecular mobility observed on the membrane of virus-like vesicles by Urbančič, I, Brun, J, Shrestha, D, Waithe, D, Eggeling, C, Chojnacki, J

Lipid composition but not curvature is a determinant of a low molecular mobility within HIV-1 lipid envelope by Urbančič, I, Brun, J, Shrestha, D, Waithe, D, Eggeling, C, Chojnacki, J

Iminosugars counteract the downregulation of the interferon gamma receptor by dengue virus by Miller, J, Hill, M, Brun, J, Pountain, A, Sayce, A, Zitzmann, N

The lithosphere under stress - General discussion by Karson, J, Brun, J, Sawyer, D, Watts, A, Wagner, A, Hardman, R, White, R, White, N

Human basigin (CD147) does not directly interact with SARS-CoV-2 spike glycoprotein by Ragotte, RJ, Pulido, D, Donnellan, FR, Gorini, G, Davies, H, Brun, J, King, LDW, Skinner, K, Draper, SJ

Assessing antigen structural integrity through glycosylation analysis of the SARS-CoV-2 viral spike by Brun, J, Vasiljevic, S, Gangadharan, B, Hensen, M, Chandran, A, Hill, M, Kiappes, J, Dwek, R, Alonzi, D, Struwe, W, Zitzmann, N

Exploring the potential of iminosugars as antivirals for Crimean-Congo haemorrhagic fever virus, using the surrogate Hazara virus: liquid-chromatography-based mapping of viral N-gl... by Tyrrell, BE, Kumar, A, Gangadharan, B, Alonzi, D, Brun, J, Hill, M, Bharucha, T, Bosworth, A, Graham, V, Dowall, S, Miller, JL, Zitzmann, N

Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly... by Brun, J, Arman, BY, Hill, ML, Kiappes, JL, Alonzi, DS, Makower, LL, Witt, KD, Gileadi, C, Rangel, V, Dwek, RA, Von Delft, A, Zitzmann, N

The spike-ACE2 interaction underlying SARS-CoV-2 infection and inhibition is enhanced by intermolecular cross linking by Asor, R, Olerinyova, A, Kushwah, MS, Soltermann, F, Rudden, LP, Vasiljevic, S, Brun, J, Hensen, M, Hill, M, Degiacomi, M, Zitzmann, N, Struwe, WB, Kukura, P

The spike-ACE2 interaction underlying SARS-CoV-2 infection and inhibition is enhanced by intermolecular cross linking by Asor, R, Olerinyova, A, Kushwah, MS, Soltermann, F, Powell Rudden, L, Vasiljevic, S, Brun, J, Hensen, M, Hill, M, Degiacomi, M, Zitzmann, N, Struwe, WB, Kukura, P

Human basigin (CD147) does not directly interact with SARS-CoV-2 spike glycoprotein by Ragotte, R, Pulido, D, Donnellan, F, Hill, M, Gorini, G, Davies, H, Brun, J, McHugh, K, King, L, Skinner, K, Miura, K, Long, C, Zitzmann, N, Draper, S

Oligomerization-driven avidity correlates with SARS-CoV-2 cellular binding and inhibition by Asor, R, Olerinyova, A, Burnap, SA, Kushwah, M, Soltermann, F, Rudden, LSP, Hensen, M, Vasiljevic, S, Brun, J, Hill, M, Chang, L, Dejnirattisa, W, Supasa, P, Mogkolsapaya, J, Zhou, D, Stuart, D, Screaton, GR, Degiacomi, M, Zitzmann, N, Benesch, J, Struwe, W, Kukura, P

A quinolin-8-ol sub-millimolar inhibitor of UGGT, the ER glycoprotein folding quality control checkpoint by Guay, KP, Ibba, R, Kiappes, JL, Vasiljević, S, Bonì, F, De Benedictis, M, Zeni, I, Le Cornu, JD, Hensen, M, Chandran, AV, Kantsadi, AL, Caputo, AT, Blanco Capurro, JI, Bayo, Y, Hill, JC, Hudson, K, Lia, A, Brun, J, Withers, SG, Martí, M, Biasini, E, Santino, A, De Rosa, M, Milani, M, Modenutti, CP, Hebert, DN, Zitzmann, N, Roversi, P

Turning high-throughput structural biology into predictive inhibitor design by Saar, KL, McCorkindale, W, Fearon, D, Boby, M, Barr, H, Ben-Shmuel, A, London, N, von Delft, F, Chodera, JD, Lee, AA, Koekemoer, L, Krojer, T, Fairhead, M, MacLean, EM, Thompson, A, Smilova, MD, Wright, N, von Delft, A, Gileadi, C, Schofield, CJ, Salah, E, Malla, TR, Tumber, A, John, T, Vakonakis, I, Kantsadi, AL, Zitzmann, N, Brun, J, Kiappes, JL, Hill, M, Witt, KD, Alonzi, DS, Makower, LL, Giroud, C, Bennett, J, Fedorov, O, Morris, GM, Ferla, M, Carbery, A, Cattermole, E, Taylor, JC, Brewitz, L

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors by Boby, ML, Fearon, D, Ferla, M, Filep, M, Koekemoer, L, Robinson, MC, Chodera, JD, Lee, AA, London, N, von Delft, A, von Delft, F, Achdout, H, Aimon, A, Alonzi, DS, Arbon, R, Aschenbrenner, JC, Balcomb, BH, Bar-David, E, Barr, H, Ben-Shmuel, A, Bennett, J, Bilenko, VA, Borden, B, Boulet, P, Bowman, GR, Brewitz, L, Brun, J, Bvnbs, S, Calmiano, M, Carbery, A, Carney, DW, Cattermole, E, Chang, E, Chernyshenko, E, Clyde, A, Coffland, JE, Cohen, G, Cole, JC, Contini, A, Cox, L, Croll, TI, Cvitkovic, M, De Jonghe, S, Dias, A, Donckers, K, Dotson, DL, Douangamath, A, Duberstein, S, Dudgeon, T, Fairhead, M, Taylor, JC, Zitzmann, N